Shire (LON:SHP) had its price target lowered by Berenberg Bank from GBX 6,000 ($82.90) to GBX 4,500 ($62.17) in a research report sent to investors on Friday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.
SHP has been the subject of several other reports. JPMorgan Chase & Co. cut Shire to a neutral rating and reduced their target price for the company from GBX 5,000 ($69.08) to GBX 3,600 ($49.74) in a research note on Tuesday, February 20th. Shore Capital restated a buy rating on shares of Shire in a research note on Monday, November 13th. HSBC reduced their price objective on Shire from GBX 4,050 ($55.95) to GBX 3,800 ($52.50) and set a hold rating on the stock in a research note on Tuesday, November 21st. Deutsche Bank restated a buy rating on shares of Shire in a research note on Monday, December 11th. Finally, Citigroup restated a buy rating and set a GBX 5,500 ($75.99) price objective on shares of Shire in a research note on Friday, January 5th. Five investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Shire has an average rating of Buy and an average target price of GBX 4,985.29 ($68.88).
Shire (SHP) opened at GBX 2,983.75 ($41.22) on Friday. The company has a market capitalization of $27,150.00 and a P/E ratio of 2,057.76. Shire has a one year low of GBX 2,940.50 ($40.63) and a one year high of GBX 5,067 ($70.01).
In related news, insider Dominic Blakemore bought 165 shares of the company’s stock in a transaction on Tuesday, December 19th. The shares were purchased at an average cost of GBX 3,790 ($52.36) per share, with a total value of £6,253.50 ($8,639.82).
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.